Integral Diagnostics (IDX) Aandelenoverzicht
Integral Diagnostics Limited, een bedrijf dat diensten verleent op het gebied van gezondheidszorg, levert diagnostische beeldvormingsdiensten aan huisartsen, medische specialisten en professionals in de gezondheidszorg en hun patiënten in Australië en Nieuw-Zeeland. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 2/6 |
Beloningen
Risicoanalyse
IDX Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Integral Diagnostics Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | AU$2.22 |
| 52 Week Hoogtepunt | AU$3.07 |
| 52 Week Laag | AU$1.91 |
| Bèta | 0.14 |
| 1 maand verandering | 6.73% |
| 3 maanden verandering | 2.30% |
| 1 Jaar Verandering | -17.16% |
| 3 jaar verandering | -30.63% |
| 5 jaar verandering | -58.03% |
| Verandering sinds IPO | 21.31% |
Recent nieuws en updates
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.Recent updates
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.IDX: Inorganic Expansion And Merger Synergies Will Drive Future Upside
Analysts have trimmed their price target for Integral Diagnostics from around A$3.36 to about A$3.12, reflecting updated assumptions for slightly lower revenue growth, modestly softer profit margins and a reduced future P/E multiple. What's in the News Management is actively assessing M&A options and continuing to look at inorganic growth, alongside opening 3 new greenfield sites in the last quarter of the financial year in Eastwood Private Hospital (South Australia), Wangaratta (Victoria) and Maroochydore (Queensland), plus a relocation to a new facility in Launceston (Key Developments).Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Despite a sharp reduction in projected revenue growth, the consensus future P/E multiple for Integral Diagnostics has contracted significantly, supporting a higher analyst price target of A$3.34. Valuation Changes Summary of Valuation Changes for Integral Diagnostics The Consensus Analyst Price Target has risen from A$3.12 to A$3.34.
Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch
Integral Diagnostics Limited ( ASX:IDX ) shareholders that were waiting for something to happen have been dealt a blow...Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Key Insights Integral Diagnostics will host its Annual General Meeting on 28th of November Total pay for CEO Ian Kadish...Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced that on 4th of April, it will be paying a dividend ofA$0.025...These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
While Integral Diagnostics Limited ( ASX:IDX ) might not be the most widely known stock at the moment, it saw...Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced it will be reducing its dividend payable on the 4th of April to...Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Does the February share price for Integral Diagnostics Limited ( ASX:IDX ) reflect what it's really worth? Today, we...Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
The performance at Integral Diagnostics Limited ( ASX:IDX ) has been quite strong recently and CEO Ian Kadish has...Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Rendement voor aandeelhouders
| IDX | AU Healthcare | AU Markt | |
|---|---|---|---|
| 7D | 0% | 0.9% | 1.3% |
| 1Y | -17.2% | -2.4% | 3.0% |
Rendement versus industrie: IDX presteerde slechter dan de Australian Healthcare -sector, die het afgelopen jaar een rendement van -2.4 % opleverde.
Rendement versus markt: IDX presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 3 % opleverde.
Prijsvolatiliteit
| IDX volatility | |
|---|---|
| IDX Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 4.6% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.8% |
Stabiele aandelenkoers: IDX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Australian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van IDX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1967 | 3,000 | Jason Martinez | www.integraldiagnostics.com.au |
Integral Diagnostics Limited, een bedrijf dat diensten verleent op het gebied van gezondheidszorg, levert diagnostische beeldvormingsdiensten aan huisartsen, medische specialisten en professionals in de gezondheidszorg en hun patiënten in Australië en Nieuw-Zeeland. Het bedrijf biedt magnetische resonantiebeeldvorming, positronemissietomografie, mammografie met computertomografie, interventionele radiologie, echografie en radiografie, zoals röntgenstralen en EOS. Integral Diagnostics Limited werd opgericht in 1967 en het hoofdkantoor is gevestigd in Melbourne, Australië.
Integral Diagnostics Limited Samenvatting
| IDX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | AU$826.92m |
| Inkomsten(TTM) | AU$14.03m |
| Inkomsten(TTM) | AU$767.82m |
Is IDX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| IDX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | AU$767.82m |
| Kosten van inkomsten | AU$525.98m |
| Brutowinst | AU$241.84m |
| Overige uitgaven | AU$227.82m |
| Inkomsten | AU$14.03m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Aug 25, 2026
| Winst per aandeel (EPS) | 0.038 |
| Brutomarge | 31.50% |
| Nettowinstmarge | 1.83% |
| Schuld/Eigen Vermogen Verhouding | 50.1% |
Hoe presteerde IDX op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/12 18:37 |
| Aandelenkoers aan het einde van de dag | 2026/08/12 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Integral Diagnostics Limited wordt gevolgd door 23 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |